These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 15270660)
1. Role of FDG-PET in the diagnosis and management of lung cancer. Oyen WJ; Bussink J; Verhagen AF; Corstens FH; Bootsma GP Expert Rev Anticancer Ther; 2004 Aug; 4(4):561-7. PubMed ID: 15270660 [TBL] [Abstract][Full Text] [Related]
2. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902 [TBL] [Abstract][Full Text] [Related]
3. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727 [TBL] [Abstract][Full Text] [Related]
4. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746 [TBL] [Abstract][Full Text] [Related]
5. Response to radiation. Rosenzweig KE; Fox JL; Giraud P Semin Radiat Oncol; 2004 Oct; 14(4):322-5. PubMed ID: 15558507 [TBL] [Abstract][Full Text] [Related]
6. Value of FDG PET in the management of NSCLC. Ukena D; Hellwig D Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785 [TBL] [Abstract][Full Text] [Related]
7. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Mac Manus MP; Hicks RJ; Ball DL; Kalff V; Matthews JP; Salminen E; Khaw P; Wirth A; Rischin D; McKenzie A Cancer; 2001 Aug; 92(4):886-95. PubMed ID: 11550162 [TBL] [Abstract][Full Text] [Related]
8. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203 [TBL] [Abstract][Full Text] [Related]
9. FDG-PET in staging lung cancer: how does it change the algorithm? Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382 [TBL] [Abstract][Full Text] [Related]
10. FDG PET: advantages for staging the mediastinum? Franzius C Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784 [TBL] [Abstract][Full Text] [Related]
11. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer]. Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692 [TBL] [Abstract][Full Text] [Related]
12. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Aquino SL; Fischman AJ Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753 [TBL] [Abstract][Full Text] [Related]
13. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Wiering B; Ruers TJ; Oyen WJ Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664 [TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Farrell MA; McAdams HP; Herndon JE; Patz EF Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716 [TBL] [Abstract][Full Text] [Related]
15. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870 [TBL] [Abstract][Full Text] [Related]
16. [Preliminary study of 18F-FDG PET-CT in defining lymph node radiation target volume for non-small-cell lung cancer patients]. Liu LP; Yu JM; Guo HB; Fu Z; Han AQ; Yang GR Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):453-6. PubMed ID: 17974282 [TBL] [Abstract][Full Text] [Related]
17. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242 [TBL] [Abstract][Full Text] [Related]
18. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555 [TBL] [Abstract][Full Text] [Related]
19. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537 [TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Vansteenkiste JF; Stroobants SG Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]